Considering that non-small cell lung cancer (NS-CLC) is the leading cause of cancer-related mortality [1], numerous clinical approaches have been implemented to enhance patient outcomes, including the combination of two oncologic procedures such as in the promising intraoperative radiotherapy, alongside the ongoing effort to establish a novel immunotherapeutic agent for NSCLC [2,3].